You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, January 2014
|
| DOI | 10.1007/s00280-014-2380-5 |
| Pubmed ID | |
| Authors |
Edward Sausville, Patricia LoRusso, Michael Carducci, Judith Carter, Mary F. Quinn, Lisa Malburg, Nilofer Azad, David Cosgrove, Richard Knight, Peter Barker, Sonya Zabludoff, Felix Agbo, Patricia Oakes, Adrian Senderowicz |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Unknown | 106 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 24 | 22% |
| Researcher | 24 | 22% |
| Student > Bachelor | 12 | 11% |
| Student > Master | 10 | 9% |
| Other | 7 | 7% |
| Other | 9 | 8% |
| Unknown | 21 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 24 | 22% |
| Medicine and Dentistry | 22 | 21% |
| Agricultural and Biological Sciences | 14 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 8% |
| Chemistry | 3 | 3% |
| Other | 9 | 8% |
| Unknown | 26 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2022.
All research outputs
#7,538,708
of 25,837,817 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#646
of 2,608 outputs
Outputs of similar age
#82,238
of 326,351 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#6
of 23 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,608 research outputs from this source. They receive a mean Attention Score of 4.5. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,351 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.